Axcan Pharma Inc - Report of Foreign Issuer (6-K)
February 14 2008 - 3:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the
month of February, 2008
Commission
File Number 0-30860
Axcan Pharma Inc.
(Exact
Name of Registrant)
597,
boul, Laurier, Mont-Saint-Hilaire (Québec), Canada J3H 6C4
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F
o
Form 40-F
x
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as
permitted by
Regulation
S-T Rule 101(b)(1):
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by
Regulation
S-T Rule 101(b)(7):
o
Indicate by check mark
whether the registrant by furnishing the information contained in this Form is
also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes
o
No
x
If
“Yes” is marked, indicate the file number assigned to the registrant in
connection with Rule 12g3-2(b):
82-
EXHIBITS
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Report on Voting Results pursuant to
Section 11.3 of National Instrument 51-102 – Continuous Disclosure
Obligations, as distributed to Autorités Des Marchés Financiers, British
Columbia Securities Commission, Alberta Securities Commission, Manitoba
Securities Commission, Ontario Securities Commission, Saskatchewan Securities
Commission, New Brunswick Securities Commission, Nova Scotia Securities
Commission, Registrar of Securities, P.E.I. and Government of
Newfoundland & Labrador on February 11, 2008.
|
|
|
|
|
|
99.2
|
|
February 13, 2008 press release entitled “Axcan
and TPG Capital Receive Investment Canada Act Approval in Connection with
Proposed Acquisition.”
|
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Date: February 14,
2008
|
By:
|
/s/ Richard Tarte
|
|
|
Name:
|
Richard Tarte
|
|
|
Title:
|
Vice President, Corporate Development
and General Counsel
|
3
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Nov 2023 to Nov 2024
